Clinical Efficacy of SARS-CoV-2 Vaccination in Hemodialysis Patients.
Clinical Efficacy of SARS-CoV-2 Vaccination in Hemodialysis Patients.
复制标题
血液透析患者接种SARS-CoV-2疫苗的临床疗效
DOI：
10.1016/j.ekir.2022.07.007
复制
发表时间：
2022-10
影响因子：
6
通讯作者：
Herrera, Patricio
中科院分区：
文献类型：
--
作者：
Torres, Ruben;Toro, Luis;Eugenia Sanhueza, Maria;Lorca, Eduardo;Ortiz, Mireya;Pefaur, Jacqueline;Clavero, Rene;Machuca, Eduardo;Gonzalez, Fernando;Herrera, Patricia;Mocarquer, Alfredo;Frias, Alondra;Roessler, Eric;Munoz, Carolina;Nunez, Miguel;Aravena, Cesar;Quintana, Enrique;Lemus, Juan;Lillo, Mario;Reynolds, Enrique;Morales, Alvaro;Pais, Edgard;Fiabane, Andrea;Parra-Lucares, Alfredo;Garrido, Cristian;Mendez-Valdes, Gabriel;Villa, Eduardo;Mansilla, Rodrigo;Sotomayor, Germana;Gonzalez, Marcela;Miranda, Cecilia;Briones, Eduardo;Gomez, Esteban;Mezzano, Sergio;Bernales, Waldo;Rocca, Ximena;Espinoza, Oscar;Zuniga, Eric;Aragon, Henry;Badilla, Marta;Valenzuela, Marcela;Escobar, Luis;Zamora, Daniela;Flores, Ivan;Tapia, Beatriz;Borquez, Tamara;Herrera, Patricio
COVID-19疫情是一个全球性的公共卫生问题。接受血液透析的终末期肾病患者的感染和死亡风险高于一般人群。在世界范围内，已经开展了一项疫苗接种运动，该运动已被证明可以减少一般人群的严重感染和死亡。然而，目前关于血液透析人群接种疫苗的临床疗效的数据有限。在智利进行了一项全国性多中心观察队列研究，以评价2021年2月至2021年8月期间接受慢性血液透析的终末期肾病患者接种抗SARS-CoV-2疫苗的临床疗效。此外，还对BNT 162 b2（Pfizer-BioNTech）和CoronaVac（Sinovac）疫苗进行了评价。确定了疫苗接种在预防SARS-CoV-2感染、住院和COVID-19相关死亡方面的有效性。共评价了12，301例患者; 10，615例（86.3%）接受了完整疫苗接种（2剂），490例（4.0%）接受了不完整疫苗接种，1196例（9.7%）未接种。在随访期间，1362例（11.0%）患者发生COVID-19，150例死亡（病死率：11.0%）。完全接种预防感染的有效率为18.1%（95%置信区间[CI]：11.8-23.8%），预防死亡的有效率为66.0%（95% CI：60.6-70.7%）。当比较两种疫苗时，BNT 162 b2和CoronaVac在减少与COVID-19相关的感染和死亡方面是有效的。然而，与CoronaVac相比，BNT 162 b2疫苗在预防感染（42.6% vs. 15.0%）和死亡（90.4% vs. 64.8%）方面具有更高的效力。我们的研究结果表明，在长期血液透析患者中接种SARS-CoV-2疫苗可有效预防与COVID-19相关的感染和死亡。
The COVID-19 pandemic is a global public health problem. Patients with end-stage renal disease on hemodialysis are at a higher risk of infection and mortality than the general population. Worldwide, a vaccination campaign has been developed that has been shown to reduce severe infections and deaths in the general population. However, there are currently limited data on the clinical efficacy of vaccinations in the hemodialysis population. A national multicenter observational cohort was performed in Chile to evaluate the clinical efficacy of anti-SARS-CoV-2 vaccination in end-stage renal disease patients on chronic hemodialysis from February 2021 to August 2021. In addition, the BNT162b2 (Pfizer-BioNTech) and CoronaVac (Sinovac) vaccines were evaluated. The efficacy of vaccination in preventing SARS-CoV-2 infection, hospitalizations, and deaths associated with COVID-19 was determined. A total of 12,301 patients were evaluated; 10,615 (86.3%) received a complete vaccination (2 doses), 490 (4.0%) received incomplete vaccination, and 1196 (9.7%) were not vaccinated. During follow-up, 1362 (11.0%) patients developed COVID-19, and 150 died (case fatality rate: 11.0%). The efficacy of the complete vaccination in preventing infection was 18.1% (95% confidence interval [CI]:11.8–23.8%), and prevention of death was 66.0% (95% CI:60.6–70.7%). When comparing both vaccines, BNT162b2 and CoronaVac were effective in reducing infection and deaths associated with COVID-19. Nevertheless, the BNT162b2 vaccine had higher efficacy in preventing infection (42.6% vs. 15.0%) and deaths (90.4% vs. 64.8%) compared to CoronaVac. The results of our study suggest that vaccination against SARS-CoV-2 in patients on chronic hemodialysis was effective in preventing infection and death associated with COVID-19.
登录
查看更多内容
影响因子：
19.6
作者：
Ng, Jia H.;Hirsch, Jamie S.;Fishbane, Steven
通讯作者：
Fishbane, Steven
影响因子：
3.4
作者：
Alfano G;Ferrari A;Magistroni R;Fontana F;Cappelli G;Basile C
通讯作者：
Basile C
DOI：
10.1056/nejmoa2105000
发表时间：
2021-06-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hacisuleyman E;Hale C;Saito Y;Blachere NE;Bergh M;Conlon EG;Schaefer-Babajew DJ;DaSilva J;Muecksch F;Gaebler C;Lifton R;Nussenzweig MC;Hatziioannou T;Bieniasz PD;Darnell RB
通讯作者：
Darnell RB
影响因子：
19.6
作者：
Clarke CL;Prendecki M;Dhutia A;Gan J;Edwards C;Prout V;Lightstone L;Parker E;Marchesin F;Griffith M;Charif R;Pickard G;Cox A;McClure M;Tedder R;Randell P;Greathead L;Guckian M;McAdoo SP;Kelleher P;Willicombe M
通讯作者：
Willicombe M
影响因子：
6
作者：
Kakkanattu TJ;Sankarasubbaiyan S;Yadav AK;Kundu M;Gowda Bg M;Kumar V;Shah K;Jha V
通讯作者：
Jha V